Intravenous Versus Oral Iron Therapy in Hemodialysis Patients

Inclusion Criteria: * Age \>18 years * Hemodialysis for at least 3 months * Hemoglobin levels between 8 and 11.5 g/dl inclusive * Transferrin saturation (TSAT) \<50% and ferritin \<800 mg/dl * Stable dose of epoetin of any types and iron therapy for at least 1 month Exclusion Criteria: * History of iron allergy * Pregnant or lactating women * Patients with known hematologic disorders other than anemia of renal disease and iron deficiency anemia * Patients with hemoglobinopathy e.g., thalassemia * Patients with iron overload or hemochromatosis * Patients with gastrointestinal hemorrhage during 6 months before enrolment in to the study * Patients with current severe infection * Patients with any malignancies * Patients with severe psychiatric illness * Patients with any other medical condition which, in the Investigator's judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes * Patients who currently receive medications that can altered gastrointestinal absorption of oral iron e.g., aluminum carbonate, aluminum hydroxide, chloramphenicol, dimercaprol